Quantitative Evaluation of the Progression of Liver Disease, Using ShearWaveTM

Quantitative Evaluation of Liver Disease With Liver and Kidney Elastography Using the Supersonic Imagine Aixplorer ShearWaveTM Elastography Ultrasound Machine

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02070315

Enrollment

1247

Registered

2014-02-25

Start date

2012-02-01

Completion date

2022-04-28

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Liver Disease

Keywords

heart failure, liver failure, post liver transplant

Brief summary

Liver biopsy for the assessment of fibrosis has multiple limitations. Liver ShearWaveTM Elastography may provide a non-invasive, fast, and reproducible alternative for the quantitative assessment of liver fibrosis.

Detailed description

To obtain a quantitative evaluation of the progression of liver disease, using ShearWaveTM Elastography measurements obtained with the Supersonic Imagine Aixplorer ultrasound machine. To compare the glomerular filtration rate and the quantitative evaluation of the progression of renal disease, using ShearWaveTM Elastography measurements obtained with the Supersonic Imagine Aixplorer ultrasound machine in post-liver transplantation patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Males and Females over the age of 18 * Patients of Liver Consultant's of Texas Dallas office, with chronic liver disease or liver transplant patient seen in Liver Transplant Clinic * Patients diagnosed with heart failure

Exclusion criteria

\- Any person unable to provide an informed consent

Design outcomes

Primary

Measure	Time frame	Description
Shearwave Elastography Ultrasound	1 day	Patients will have a scan performed at their regularly scheduled clinic visits.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJames Trotter, MD

Baylor Health Care System

Outcome results